Last reviewed · How we verify
NCT05815394
177Lu-labeled NY108 SPECT Imaging in Patients
EARLY_PHASE1 trial testing 177Lu-labeled NY108 in Prostate Cancer in 10 participants. Status unknown.
3 March 2024
Quick facts
| Lead sponsor | Affiliated Hospital of Jiangnan University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 3 March 2023 |
| Primary completion | 3 March 2024 |
| Estimated completion | 12 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- 177Lu-labeled NY108 — full drug profile →
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Affiliated Hospital of Jiangnan University
Who can join
Adults 18 to 75, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single arm study to evaluate the safety and biodistribution of 177Lu-labeled NY108 (177Lu-NY108) SPECT Imaging in patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Current clinical application of lutetium‑177 in solid tumors (Review).
Niu T, Fan M, Lin B, Gao F, et al · · 2024 · cited 13× · PMID 38596660 · DOI 10.3892/etm.2024.12514
Verify or expand the search:
- PubMed search for NCT05815394
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Affiliated Hospital of Jiangnan University trials
Trials by the same sponsor.
- NCT07023861 — The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies · EARLY_PHASE1 · enrolling by invitation
- NCT07023848 — PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors · EARLY_PHASE1 · enrolling by invitation
- NCT07162779 — Evaluation of [68Ga]DOTA-IR-780-C-4 in PET Imaging Studies for PSMA-Positive Prostate Cancer Patients · NA · enrolling by invitation
- NCT06448975 — An Exploratory Study of Deep Cervical Lymphovenous Bypass (LVB) in Alzheimer's Disease · NA · recruiting
- NCT06723665 — The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05815394 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Affiliated Hospital of Jiangnan University
- Last refreshed: 18 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05815394.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing